7 / 32
Acquired resistance to EGFR TKI
Gefitinib +
Cisplatin / Pem
Gefitinib until
PD
Placebo +
Cisplatin / Pem
Placebo until PD
1:1 randomisation
•
PD on gefitinib by RECIST
criteria
•
Measurable stage IIIB / IV
disease
•
ECOG 0-1
•
Activating
EGFR
mutations
N=265
Soria Lancet Oncol 15, Mok JCO 17
PFS:
5.4
vs.
5.4
HR 0.86, p=0.273
OS:
13.4
vs.
.
19.5
HR 1.44, p=0.016
IMPRESS phase III trial
OS results may be driven for T790M + (plasma)
patients